Zhonghua Yi Xue Za Zhi. 2025 Dec 2;105(44):4041-4047. doi: 10.3760/cma.j.cn112137-20250405-00836.
ABSTRACT
Objective: To explore the effectiveness and safety of anlotinib combination regimens in patients with previously immunotherapy treated advanced non-small cell lung cancer (NSCLC). Methods: This study retrospectively included 85 patients with previously immunotherapy treated advanced NSCLC who received anlotinib combination regimens or single-agent chemotherapy in the First Affiliated Hospital of Zhengzhou University from October 2018 to October 2023. The observation group was consisted of 43 patients who received anlotinib combination regimens, and the control group was consisted of 42 patients who received single-agent chemotherapy. Observation group received anlotinib combined with chemotherapy and anlotinib combined with immunotherapy, while control group received single-agent chemotherapy. The follow-up period ended on May 25, 2024. The baseline characteristics, recent effectiveness, prognosis, and adverse reactions were compared between the observation group and the control group. Survival curves were plotted using the Kaplan-Meier method, and the log-rank test was used to compare the differences. Results: In observation group, there were 29 males and 14 females with a median age [M (Q1, Q3)] of 63 (27, 73) years; in control group, there were 27 males and 15 females, with a median age of 64 (28, 73) years. Objective response rates for the observation group and control group were 23.3% (10/43) and 14.3% (6/42), respectively, with no statistically significant difference (P=0.290). Disease control rates were 83.7% (36/43) and 57.1% (24/42) for the observation and the control groups, respectively, with a statistically significant difference (P=0.007). The median follow-up duration for the observation group and the control group was 14.2 and 9.6 months, respectively. Prognosis results indicated that the median PFS for the observation group and the control group were 6.1 (95%CI: 2.41-9.79) and 2.9 months (95%CI: 2.59-3.21), respectively. The observation group was significantly higher than the control group (P=0.009). The median OS were 15.5 (95%CI: 8.99-22.01) and 10.3 months (95%CI: 7.87-12.74), respectively. The observation group was also significantly higher than the control group (P=0.016). Safety analysis results exhibited that the incidence of adverse reactions of different grades in the observation group and control groups were 88.4% (38/43) and 81.0% (34/42), respectively; The grade ≥3 adverse reactions occurred in 41.9% (18/43) and 33.3% (14/42), respectively, with no statistically significant difference (both P>0.05). The grade≥3 adverse reactions were controlled through dose adjustment and symptomatic treatment. Conclusion: In patients with previously immunotherapy treated advanced NSCLC, anlotinib combination regimens demonstrates preliminary efficacy and tolerable safety profile compared to single-agent chemotherapy.
PMID:41320658 | DOI:10.3760/cma.j.cn112137-20250405-00836
